Research & Reviews: Journal of Hospital and Clinical Pharmacy

Bio Immune (G)Ene Medicine-Bi(G) Med-Can Neutralize Bacterial Agents by Beating them at their Own Game

Gilbert Glady
European Bio Immune(G)ene Medicine Association, France, info@ebma-europe.com

Extended Abstract

Abstract

In recent years, several discoveries have deeply modified our data on the relationships between bacterium and our cells, whether or not they area unit immuno-competent cells or alternative corporeal cells that area unit subject to microorganism attack. we have a tendency to currently higher savvy our cells find microorganism aggressors mistreatment receptors of restricted specificity happiness to natural immunity and able to determine specific molecular patterns settled on microorganism membranes, being gram-positive or negative germs or mycobacteria. Once this identification has been distributed, an entire arsenal of inflammatory reactions is triggered so as to destroy as quickly as potential microorganism germs in their aggression part. featured with these defensive ways deployed by the innate system, bacterium don't stay inactive and successively implement a group of molecular reactions, as well as the mighty system of injectisomes, to elude the immune responses aiming at their neutralization or maybe their final destruction. What if, for a therapeutic purpose, we have a tendency to might counteract the ways enforced by bacterium to beat them at their own game? this can be what the Bio Immune(G)ene Medicine-in short BI(G)MED- is making an attempt to try to to quite with success by mistreatment ultra-low doses of molecules and wishing on the overall principle of Hormesis. A brief description of the strategy and a few clinical examples can facilitate to raised perceive the deserves of this sub-lingual nanotherapy, that is furthermore destitute of any undesirable aspect effects.

The term microorganism reactivation is way from being wide accepted by the scientific community maybe this is often because of associate degree initial linguistics misunderstanding of the notions of infection and reactivation, the second not being a selected type of the primary, however one thing terribly totally different returning below a permanent however somehow restrained conflict existing between a latent and repeated virus and also the system. EBV is among all viruses the one wherever the conception of reactivation applies the most effective, with its ordination being of consistent size and extremely adaptive , able to modulate varied sorts of latency, to mimic the immune reactions engaged against him, to integrate into cellular desoxyribonucleic acid to regulate it and ultimately immortalize the carrying cell. This microorganism reactivation, expression of a conflict whose outcome can long stay unsure, are able to generate an outsized variety of pathological disorders, starting from a banal chronic fatigue syndrome to malignancies, to an outsized variety of auto-immune diseases. Once the biological designation has been created, it's vital to implement a treatment capable of neutralizing the aggressor and preventing it from initiating the pathophysiological processes liable for the mentioned higher than disorders. This risk exists these days by resorting to a medical care victimization radical low doses of varied sorts of immunocompetent molecules, however additionally of epigenetic regulators like non-coding RNAs being of microorganism origin or happiness to the host cell. Some clinical examples build it doable to higher specify the therapeutic procedure used and to emphasise its biological effectiveness.

Asthma is one of the diseases that demonstrates a decent vary of variation in its clinical expression, to boot to a vital unsimilarity among the pathophysiological mechanisms gift in each case. The ever-increasing knowledge of the molecular signalling routes and so the event of the Bio Immune(G)ene medication [BI(G)MED] treatment in line with this knowledge has unconcealed a whole novel potential set of self-regulation biological molecules, which is able to be accustomed promote the physiological immunogenic self-regulation mechanisms and re-establish the equilibrium balance at a genomic, proteomic and cellular level. The aim of this study is to demonstrate that the articulator use of a therapeutic protocol supported BI(G)MED restrictive BIMUREGs among the treatment of chronic respiratory illness would possibly trim or suppress steroid treatment and avoid its harmful aspect effects that some patients suffer once victimization this treatment on a

semipermanent basis. The clinical powerfulness of BI(G)MED for chronic respiratory illness was evaluated through a multi-centre study applied in 2016 implementing a 6-month BI(G)MED treatment protocol for respiratory illness. a whole of sixty-one patients from private medical centres and of European countries yet as land, Austria, France, Kingdom of European nation and Kingdom of Spain participated. The manuscript describes well the clinical powerfulness of Bio Immune(G)ene restrictive BI(G)MED treatment protocol that allows the reduction or total removal of the steroid dose in patients with chronic respiratory illness. No adverse reactions were discovered. The BI(G)MED restrictive treatment brings novel therapeutic potentialities as a decent and safe treatment of chronic respiratory illness. BI(G)MED was demonstrable to significantly trim respiratory illness severity once parameter compositions were all analysed by categorical outcomes. Therefore, it's thought of a good therapeutic numerous for patients administrative body respond poorly to steroids.

Biography

Gilbert Glady has graduate from Med School in 1977 and has completed his MD at the age of 27 years from Strasbourg University of medicine and postdoctoral studies from Besancon and Paris-Nord universities of medicine and was then an Intern in Onco-Hematology in the university clinic for several years. After a specialization in homeopathy and naturopathy in Paris, he returned to the Alsace region to work as a Private Practitioner. Through his work and encounters, he developed interest and expertise in Immunology and Immunogenetics that leaded him to nanomedicine and nanobiotechnology. He thus became in 2010, the Creator of the BI(G)MED method (Bio Immune (G)ene Medicine) and Director of EBMA, the European association responsible for communication and trainings in the field of BI(G) MED. He has participated in numerous international congresses in immuno-allergology, infectiology and oncology with posters and oral presentations and is the Author of several publications on nanobiotherapy in different journals.